|Name||The company is known as Merck in the United States and Canada. Everywhere else, we are known as MSD. Merck & Co., Inc. is the legal name and is listed on the New York Stock Exchange under the symbol "MRK."|
MSD is an innovative, global healthcare leader that is committed to improving health and well-being around the world.
Our core product categories include diabetes, cancer, vaccines and hospital acute care. We continue to focus our research on conditions that represent some of today’s most significant health challenges – like cancer, HIV, HPV, hepatitis C, cardio-metabolic disease, antibiotic-resistant infection and Alzheimer's disease, and we are on the front lines in the fight against emerging global pandemics, such as ebola.
We also devote extensive time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver our products to the people who need them.
At MSD, we're applying our global reach, financial strength and scientific excellence to do more of what we're passionate about: improving health and improving lives.
|Employees||Approximately 69,000 (as of Dec. 31, 2017)|
|Headquarters||Kenilworth, New Jersey|
|2017 Revenue||$40.1 billion|
(By Geographic Region)
|2017 R&D Expense||$7.3 billion (excludes restructuring and merger related expenses)|
MSD is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.
MSD has a robust pipeline, with a wide range of product candidates across each phase of development. View the pipeline.
Kenneth C. Frazier, chairman of the board, president and chief executive officer
|View the list of Executive Committee members.|